Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.48 |
| ▸ | CASP7 | P55210 | 1/20 | 0.47 |
| ▸ | CASP6 | P55212 | 1/20 | 0.47 |
| ▸ | JMJD6 | Q6NYC1 | 1/20 | 0.46 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 4/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | MC4R | P32245 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | CLK1 | P49759 | 1/20 | 0.43 |
| ▸ | GSK3A | P49840 | 1/20 | 0.43 |
| ▸ | GSK3B | P49841 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 2/20 | 0.42 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.42 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL425820 | 0.92 | MRGPRX4 (0.47) | L3MBTL1CASP7CASP6GAAMAPT | |
| SCHEMBL425301 | 0.90 | CASR (0.42) | L3MBTL1CASP7CASP6GAAMEN1 | |
| SCHEMBL430391 | 0.89 | DDR2 (0.42) | L3MBTL1TP53MEN1KMT2AKDM4E | |
| SCHEMBL430389 | 0.89 | DDR2 (0.42) | L3MBTL1TP53MEN1KMT2AKDM4E | |
| SCHEMBL425404 | 0.89 | KMO (0.45) | L3MBTL1TP53MEN1KMT2AKDM4E | |
| SCHEMBL425402 | 0.89 | KMO (0.45) | L3MBTL1TP53MEN1KMT2AKDM4E | |
| SCHEMBL425345 | 0.88 | DDR2 (0.42) | L3MBTL1CASP7CASP6SMN1; SMN2MEN1 | |
| SCHEMBL425347 | 0.88 | DDR2 (0.42) | L3MBTL1CASP7CASP6SMN1; SMN2MEN1 | |
| SCHEMBL425814 | 0.84 | SIGMAR1 (0.40) | CASP7CASP6SIGMAR1 | |
| SCHEMBL426673 | 0.84 | MAPT (0.42) | L3MBTL1PIK3CAMAPTSMN1; SMN2HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8173651-B2 | Pyridine compounds | SYNTA PHARMACEUTICALS CORPORATION (US) | 2012-05-08 | — | — | US | claimed |
| US-7687498-B2 | Pyridine compounds | SYNTA PHARMACEUTICALS CORPORATION (US) | 2010-03-30 | — | — | US | claimed |
| US-7338951-B2 | Pyridine compounds | SYNTA PHARMACEUTICALS CORP. (US) | 2008-03-04 | — | — | US | claimed |
| US-20050250774-A1 | Pyridine compounds | LSI FINANCING LLC, AS ADMINISTRATIVE AGENT | 2005-11-10 | — | — | US | claimed |
| US-20150174132-A1 | METHOD FOR TREATING B CELL REGULATED AUTOIMMUNE DISORDERS | SYNTA PHARMACEUTICALS CORP (US) | 2015-06-25 | — | — | US | disclosed |
| US-8173651-B2 | Pyridine compounds | SYNTA PHARMACEUTICALS CORPORATION (US) | 2012-05-08 | — | — | US | disclosed |
| US-20120021434-A1 | METHOD FOR TREATING B CELL REGULATED AUTOIMMUNE DISORDERS | SYNTA PHARMACEUTICALS CORP. (US) | 2012-01-26 | — | — | US | disclosed |
| US-20110098267-A1 | TOPICAL FORMULATIONS FOR THE TREATMENT OF PSORIASIS | SYNTA PHARMACEUTICALS CORPORATION (US) | 2011-04-28 | — | — | US | disclosed |
| US-20100173413-A1 | PYRIDINE COMPOUNDS | SYNTA PHARMACEUTICALS CORPORATION (US) | 2010-07-08 | — | — | US | disclosed |
| US-7687498-B2 | Pyridine compounds | SYNTA PHARMACEUTICALS CORPORATION (US) | 2010-03-30 | — | — | US | disclosed |
| US-20090163708-A1 | PROCESS FOR PREPARING MESYLATE SALTS OF IL-12 INHIBITORY COMPOUNDS | SYNTA PHARMACEUTICALS CORP. (US) | 2009-06-25 | — | — | US | disclosed |
| US-20080167300-A1 | PYRIDINE COMPOUNDS | MADRIGAL PHARMACEUTICALS, INC. | 2008-07-10 | — | — | US | disclosed |
| US-20070032493-A1 | Method for treating B cell regulated autoimmune disorders | SYNTA PHARMACEUTICALS CORP. (US) | 2007-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080167300-A1 | PYRIDINE COMPOUNDS | IL2, IL4, IL6 | L3MBTL1 4499/4885CASP7 833/4885CASP6 344/4885 |
| US-20110098267-A1 | TOPICAL FORMULATIONS FOR THE TREATMENT OF PSORIASIS | IL17A, IL23R, IL15 | L3MBTL1 4848/4885CASP7 1449/4885CASP6 2207/4885 |
| US-20150174132-A1 | METHOD FOR TREATING B CELL REGULATED AUTOIMMUNE DISORDERS | REL, NFATC1, BCL6 | L3MBTL1 1129/4885CASP7 821/4885CASP6 897/4885 |
| US-20100173413-A1 | PYRIDINE COMPOUNDS | IL2, IL4, IL6 | L3MBTL1 4499/4885CASP7 833/4885CASP6 344/4885 |
| US-20050250774-A1 | Pyridine compounds | IL2, IL4, IL6 | L3MBTL1 4499/4885CASP7 833/4885CASP6 344/4885 |
| US-20090163708-A1 | PROCESS FOR PREPARING MESYLATE SALTS OF IL-12 INHIBITORY COMPOUNDS | IL17A, IL23R, IL2 | L3MBTL1 3992/4885CASP7 229/4885CASP6 361/4885 |
| US-20070032493-A1 | Method for treating B cell regulated autoimmune disorders | REL, NFATC1, BCL6 | L3MBTL1 1129/4885CASP7 821/4885CASP6 897/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.